Literature DB >> 33588800

Changes in ocular surface and Meibomian gland after penetrating Keratoplasty.

Kang Yoon Kim1, Byunghoon Chung2, Eung Kweon Kim3,4, Kyoung Yul Seo1, Ikhyun Jun5, Tae-Im Kim6,7.   

Abstract

BACKGROUND: To acquire desirable outcomes of penetrating keratoplasty (PKP), various factors affecting graft survival, visual function, and subjective symptom should be considered. As ocular surface and meibomian gland function are associated with these factors, this study aims to investigate changes of ocular surface and meibomian gland parameters after PKP.
METHODS: This retrospective case series study included 24 eyes of 24 patients who underwent penetrating keratoplasty. Examinations on lipid layer thickness (LLT), meiboscore, tear meniscus area (TMA), tear breakup time (TBUT), corneal fluorescein staining (CFS), Schirmer I test (SIT), Ocular Surface Disease Index (OSDI), and meibomian gland functions were performed before and at 1 week, 1 month, 6 months, and 12 months after surgery.
RESULTS: Compared to baseline (2.9 ± 0.6 s), TBUTs were longer at 1 week (4.4 ± 0.5 s, P = 0.027) and 6 months (4.4 ± 0.5, P = 0.048) after surgery. CFS values improved from baseline (6.5 ± 1.1) to 6 months (3.5 ± 0.6, P = 0.023) and 12 months (3.3 ± 0.7, P = 0.001) after surgery. Meibum quality value worsened at 1 week and 12 months after surgery and meibomian gland expressibility value worsened at 1 week and 6 months after surgery compared to baseline. OSDI scores improved at 6 and 12 months after surgery. Meiboscore showed no change throughout the follow up period. The patients with high preoperative meiboscore had worse meibomian gland expressibility at 6 and 12 months and meibum quality at 6 months postoperatively compared to their baseline and to those of patients with low preoperative meiboscore.
CONCLUSIONS: After penetrating keratoplasty, ocular surface parameters including corneal staining, TBUT, and OSDI significantly improved whereas meibomian gland parameters showed deteriorations, which was marked in patients with high preoperative meiboscore. Thus, perioperative management of MGD is recommended for patients who undergo penetrating keratoplasty, especially in patients with advanced MGD.

Entities:  

Keywords:  Dry eye disease; Meibomian gland dysfunction; Penetrating keratoplasty

Mesh:

Year:  2021        PMID: 33588800      PMCID: PMC7885585          DOI: 10.1186/s12886-021-01851-4

Source DB:  PubMed          Journal:  BMC Ophthalmol        ISSN: 1471-2415            Impact factor:   2.209


  3 in total

Review 1.  Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes.

Authors:  M A Lemp
Journal:  CLAO J       Date:  1995-10

2.  Meibomian gland studies: histologic and ultrastructural investigations.

Authors:  J V Jester; N Nicolaides; R E Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  1981-04       Impact factor: 4.799

3.  Histochemical demonstration of acetylcholinesterase activity in human Meibomian glands.

Authors:  M T Perra; A Serra; P Sirigu; F Turno
Journal:  Eur J Histochem       Date:  1996       Impact factor: 3.188

  3 in total
  4 in total

1.  Dermatochalasis Aggravates Meibomian Gland Dysfunction Related Dry Eyes.

Authors:  Wan-Lin Wu; Shu-Wen Chang
Journal:  J Clin Med       Date:  2022-04-23       Impact factor: 4.964

2.  Alterations in the ocular surface and tear film following keratoplasty.

Authors:  Jay J Meyer; Akilesh Gokul; Michael T M Wang; Justin Sung; Jennifer P Craig
Journal:  Sci Rep       Date:  2022-07-14       Impact factor: 4.996

3.  Correction to: Changes in ocular surface and Meibomian gland after penetrating Keratoplasty.

Authors:  Kang Yoon Kim; Byunghoon Chung; Eung Kweon Kim; Kyoung Yul Seo; Ikhyun Jun; Tae-Im Kim
Journal:  BMC Ophthalmol       Date:  2021-03-05       Impact factor: 2.209

Review 4.  Optimization of the Ocular Surface Through Treatment of Ocular Surface Disease Before Ophthalmic Surgery: A Narrative Review.

Authors:  Barry Schechter; Francis Mah
Journal:  Ophthalmol Ther       Date:  2022-04-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.